AUA: Thermatrx Microwave Thermotherapy an Option for Patients with Benign Prostatic Hyperplasia
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




AUA: Thermatrx Microwave Thermotherapy an Option for Patients with Benign Prostatic Hyperplasia

By Lara Pullen
Special to DG News

CHICAGO, IL -- September 19, 2002 -- The Thermatrx TMx™ microwave thermotherapy system appears to be effective in reducing the symptoms of benign prostatic hyperplasia.

The TMx-2000 system is a relatively new form of periurethral transurethral microwave thermotherapy that utilizes lower levels of energy than other microwave thermotherapies. The system is minimally invasive and can be performed outpatient procedure that uses heat delivered through a microwave antenna to destroy obstructive prostate tissue

The technology is based on the discovery that cooling (a typical aspect of thermotherapy) is not required for efficacy or patient tolerance.

Dr. Nuzzarello, of Urology Associates of DuPage, in Wheaton, Illinois, presented the results of the Food and Drug Assocation (FDA) premarket approval application study for Thermatrx here today at the 76th Annual Meeting of the North Central Section of the American Urology Association.

He described Thermatrx as "an interesting new twist on microwave therapy that should be considered [for patients with BPH]."

In their one-year blinded, randomised study, Dr. Nuzzarello and colleagues included 121 patients who underwent the Thermatrx procedure and 62 patients who underwent a sham procedure.

All patients were over the age of 50 years, had American Urology Association (AUA) symptom scores greater than 12, and had experienced symptoms for more than one year.

The Thermatrx patients achieved a 45 percent reduction in AUA symptom score at three months post-treatment, and a 47 percent decrease at 12 months, compared to baseline. In addition, Thermatrx patients had a 51 percent increase in their peak flow rate at 12 months post-therapy.

"We all have patients on the internet waiting for the next best thing. Well, I think this might be it," Dr. Nuzzarello concluded.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities